European Union - English - EMA (European Medicines Agency)

shire pharmaceutical contracts limited - epoetin delta - kidney failure, chronic; anemia - antianemic preparations - dynepo is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult patients. it may be used in patients on dialysis and in patients not on dialysis.

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 20 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 40 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 60 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.

European Union - English - EMA (European Medicines Agency)

shire pharmaceutical contracts limited - anagrelide - thrombocythemia, essential - antineoplastic agents - xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (et) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.

Malta - English - Medicines Authority

shire pharmaceutical contracts limited - lanthanum - chewable tablet - lanthanum 250 mg - all other therapeutic products

Malta - English - Medicines Authority

shire pharmaceutical contracts limited - lanthanum - chewable tablet - lanthanum 500 mg - all other therapeutic products

Malta - English - Medicines Authority

shire pharmaceutical contracts limited - lanthanum - chewable tablet - lanthanum 750 mg - all other therapeutic products

Malta - English - Medicines Authority

shire pharmaceutical contracts limited - lanthanum - chewable tablet - lanthanum 1000 mg - all other therapeutic products

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceutical contracts limited - mesalazine - tablet prolonged release - 1200 milligram - mesalazine